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anisms. The development of predictive animal models and translatable neuroinflammation
biomarkers for AD would also facilitate the advancement of novel treatments for innate immunity.
Important challenges impeding the advancement of new therapeutic agents and strategies to over-
come them were discussed.
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When Alois Alzheimer peered through a microscope at
histologic sections of Auguste D’s brain over a century
ago, he saw not only the characteristic amyloid plaquesimer’s Association. This is an open access article under the CC BY-NC-ND
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of Alzheimer’s disease (AD), but also glial cells clustered
around the plaques [1]. These innate immune cells that
mediate neuroinflammation in AD—primarily microglia
and astrocytes—are now thought to play an important role
in disease pathogenesis, possibly providing novel therapeu-
tic targets that may ultimately be as important as the amyloid
and tau proteins that make up the plaques and tangles them-
selves [2]. Adaptive immunity also plays an essential role in
responding to disease or injury in the central nervous system
(CNS), although adaptive immune-system driven effects,
mediated by T and B cells, appear at present to be far
more important in neuroinflammatory diseases such as mul-
tiple sclerosis (MS) than in AD, where innate immunity ap-
pears to drive neuroinflammation.
In the early 2000s, the finding that individuals receiving
various nonsteroidal anti-inflammatory drugs (NSAIDs) for
diverse systemic inflammatory disorders had a reduced inci-
dence and prevalence of AD was noted fairly consistently in
a number of epidemiologic studies [3]. This observation in
part led to trials of NSAIDs in bothmild cognitive impairment
(MCI) and AD dementia; however, the results of these studies
were negative, dampening further investigation of this thera-
peutic strategy for almost a decade. Interest in the role of
neuroinflammation inAD has increased dramatically in recent
years, however, driven by important findings in neurobiology
and genetics, and the topic has been the focus of several recent
international symposia and reviews [2,4,5]. In April 2015,
the topic was addressed by the Alzheimer’s Association’s
Research roundtable, a partnership of experts from
academia, industry, and regulatory agencies. Participants at
the meeting examined what is currently known, including
research gaps, therapeutic opportunities, and barriers for
clinical development. This article aims to contribute to the
evolving understanding of inflammatory and immune
mechanisms in AD and their potential as therapeutic targets
by summarizing key aspects of those discussions.2. Cells and mediators of inflammation in
neurodegenerative disease
There is increasing appreciation that AD pathogenesis
and progression are not a consequence solely of neuronal
dysfunction but also involve glia-dependent neuroinflamma-
tory mechanisms. Microglia and astrocytes are the major
glial cell types that respond to disease stressors by innate im-
mune responses such as production and release of inflamma-
tory mediators. In addition, perivascular macrophages and
peripheral myeloid cell populations that can enter the
diseased brain also participate in neuroinflammatory
signaling. If not kept in check, these neuroinflammatory re-
sponses can contribute to pathology and disease progression.
Microglia were historically viewed as mainly protecting the
brain from exogenous insults, and astrocytes were seen as
primarily providing nutritive and structural support for neu-
rons. However, both cell types are now known to play mul-tiple roles in brain health. During neurodegenerative disease
processes their function may be adversely affected through
inflammatory signaling responses.2.1. Microglia
Microglia, derived from primitive hematopoietic cells in
the yolk sac, seed the brain during fetal development, expand
in numbers dramatically after birth, and are self-renewing
throughout adult life. They are the resident phagocytes of
the CNS and though sharing many properties with peripheral
tissue macrophages and monocytes, they are autonomous
from peripheral monocytes, which normally do not enter
the brain. Although phagocytosis is perhaps their best known
property, recent research has revealed multiple roles and
distinct functions for microglia in development and adult
life. In development, they remove excess synaptic connec-
tions and modulate circuit development—a role that is crit-
ical for proper brain development [6].
In the adult brain, microglia play an important role in
regulating synaptic plasticity and remodeling neuronal cir-
cuits. Another key function of microglia is to act as sentinels,
surveilling the parenchyma for danger signals, especially the
intrusion of pathogens, and contribute to homeostasis. This
capacity is facilitated by their numerous extensions (filopo-
dia) that maintain close contact with neurons, perivascular
cells, and astrocytes. They may also participate in neurogen-
esis and synaptogenesis in brain regions where this occurs,
as well as in the removal of debris resulting from (non-
neuronal) apoptotic cell death [6]. Importantly for AD, given
its preponderant onset in late-life, aging-associated changes
in the quality of these functions have been increasingly
appreciated as well.
In the face of injury and neurodegenerative disorders,
however, microglia assume a radically different phenotype.
They are rapidly activated in response to acute injury, for
example, trauma or stroke, becoming “nurturers” and “war-
riors” as well as sentinels [7]. This phenotypic alteration in-
volves both chemical and morphologic changes.
Morphologically, filopodia retract and microglia can
become actively phagocytic, participating in the resolution
of tissue damage. However, process retraction by microglia
will eliminate their ability to monitor synaptic activity,
thereby compromising the microglial contribution to
network homeostasis. The ability of microglia to change
their phenotype dramatically on activation has led to their
being referred to as a “double-edged sword.”
In AD brain, microglia (or peripherally-derived macro-
phages) have long been noted to cluster around neuritic pla-
ques but appear to have a loss of phagocytic capacity and
possibly a gain of toxic function as well [8,9]. It is important
to note that AD is a very slow process, with the interval
between the onset of amyloid b (Ab) deposition (the leading
hypothesized etiologic culprit) and dementia being
approximately 20 years [10]. Also, as far as is known, the path-
ophysiological processes are endogenous; therefore,
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for exogenous insults such as bacterial or viral infections, or
even trauma and stroke, which involve the sudden intrusion
of cells and chemicals normally not present in the brain.
Finally, AD most often develops in late life, and thus its path-
ophysiology is superimposed on the effects of aging on the
brain.
Distinct heterogeneity in microglia/macrophage re-
sponses has been shown in early-stage AD brain samples
[11]. Wilcock et al. performed qPCR analysis of a group
of putative neuroinflammatory markers, using autopsy tissue
from clinically characterized early-stage AD brains. They
grouped samples into two categories, defined by virtue of
showing different expression patterns for these markers. In
one group, expression of markers often associated with in-
flammatory responses was elevated, whereas in the other
group, expression of markers categorized in studies of pe-
ripheral macrophages as being associated with repair pro-
cesses, fibrosis, and counter-regulation of inflammatory
components was elevated. Using the same assay, they did
not see this polarization of neuroinflammatory gene expres-
sion in late-stage AD brains. Unbiased, genome-wide
expression profiling with extensive bioinformatics analysis
of these samples will help to define the tissue response to
the AD disease process over time. It can be hypothesized
that molecular heterogeneity of the CNS tissue response dur-
ing AD will enable insights leading to novel target identifi-
cation for therapeutics.
The recent identification of several genetic risk factors
involving proteins associated with microglial function has
greatly galvanized interest in the role of these cells in AD.
For example, a rare missense mutation in the gene encoding
the triggering receptor expressed on myeloid cells 2
(TREM2), which is expressed on microglia and confers an
increased risk of AD and other misfolded protein-associated
neurodegenerative diseases [12,13]. Studies using direct
ribonucleic acid (RNA) sequencing demonstrated that
TREM2 down-regulates Ab-induced microglial phagocytic
function and dysregulates these cells’ proinflammatory re-
sponses [14,15]. Furthermore, the TREM2 protein can be
measured as a soluble variant (sTREM2) in the
cerebrospinal fluid (CSF), demonstrating recent data that
CSF sTREM2 levels are increased in the early symptomatic
phase of AD, probably reflecting a corresponding change of
the microglia activation status in response to neuronal death
[16,17]. The transmembrane protein CD33 is expressed at
higher levels in AD microglia compared to age-matched con-
trols. CD33 modulates innate immunity and has been identi-
fied as another risk factor for AD (with the risk allele
leading to increased CD33 expression in microglia and mono-
cytes), presumably by promoting Ab42 accumulation [18–20].
The ATP-binding cassette transporter A7 (ABCA7) is also
highly expressed in microglia and can affect AD pathogenesis
[21]. These proteins could be therapeutic targets. For example,
lintuzumab, an antibody against CD33, can down-regulate
surface expression of CD33 [22].Other studies using direct RNA sequencing indicate that
microglia express a unique set of transcripts distinct from
peripheral mononuclear phagocytes. This includes a sensing
cluster or “sensome” of transcripts that are differentially regu-
lated during aging [23]. Interestingly, these studies have
demonstrated an aging-associated up-regulation of microglial
neuroprotective genes, including, but not limited to, neuregu-
lin and Stat 3; as well as associated down-regulation of oxida-
tive phosphorylation and neurotoxicity-associated factors.
Whether there are regional differences in subsets of microglia
that are associated with aging is not known. Also not known
is whether transcriptional changes in these and other genes
translate into functional outcomes during disease.2.2. Astrocytes
Compared to microglia, much less is known about the
role of astrocytes in AD pathogenesis. The most common
cell type in the CNS, astrocytes were historically thought
to serve essentially a nutritive role and provide structural
support and a physical scaffold for neurons. However, astro-
cytes are now known to play multiple active roles in normal
neurophysiology, including significant involvement in
neurotransmission, especially glutamatergic transmission.
They are themselves excitable, they communicate with neu-
rons by sensing neurotransmitter release and in turn
releasing their own signaling molecules (gliotransmitters),
and they are intimately associated with synapses physically.
These attributes have given rise to the term “tripartite” syn-
apse to reflect the importance of glia in neurotransmission.
In addition to intimate contact with neurons, astrocytes
also associate with the cerebrovasculature through special-
ized processes called endfeet. The astrocyte endfeet almost
completely ensheath intraparenchymal blood vessels in the
brain and are important in the maintenance of ionic and os-
motic homeostasis and gliovascular signaling [24,25].
Finally, astrocytes are in close contact with microglia as
well, and there is strong evidence for bidirectional
signaling between the two cell types.
Like microglia, astrocytes can be activated by various
stimuli, and astrocytic activation is increasingly appreci-
ated as an important element of neurodegenerative disor-
ders. Astrocytes also undergo age-related changes, on
which the pathophysiologic features of late-life neurode-
generative disorders such as AD are superimposed. Astro-
cytic involvement in neuroinflammation is characterized
by increased cytokine production and the release of
signaling molecules that affect neurons either directly or
through microglial activation. One possibly important
pathway involves NFkB-activated astrocyte release of
complement protein C3, which can bind neuronal C3aR
and induce neuron damage [26]. This suggests that inhibi-
tion of NFkB signaling or neuronal C3aR may be therapeu-
tically beneficial. Another astrocytic signaling molecule of
interest is soluble CD40 ligand, which binds to its cognate
microglial cell surface receptor. This binding in turn drives
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(TNF)-a, an important pro-inflammatory effector molecule
with recognized potential to contribute to tissue destruction
in AD, as well as possibly other important cytokines [27].3. Tools to enable discovery and translational research
and drug development
3.1. Biomarkers
New tools developed to assess the time course of neuro-
inflammation across the continuum of the disease have
both helped clarify its clinical correlates and provided poten-
tial outcome measures for clinical trials. The roundtable dis-
cussed several imaging and fluid biomarkers in development
as well as the need for additional biomarkers. The 18-kDa
translocator protein (TSPO), previously known as the pe-
ripheral benzodiazepine receptor, is a mitochondrial protein
and a marker of inflammation highly expressed on activated
microglia, activated astrocytes, and macrophages, thus mak-
ing it a putative biomarker for activation of the immune sys-
tem. A TSPO positron emission tomography (PET)
radioligand in development was used to quantify neuroin-
flammation in volunteers with AD-associated MCI. This
study showed that inflammation increases in the cortical re-
gions typically affected by plaque deposition after conver-
sion of MCI to AD [28]; it also showed increased
inflammation in AD patients with early age of onset. These
results suggest that the ligand may be useful in longitudinal
observational and interventional studies in MCI. Current
TSPO tracers have various limitations, including genotype-
specific properties, nonspecific binding, and high affinity
for targets within the cerebrovasculature that prevent access
to parenchymal targets of interest. These limitations must be
overcome if TSPO PET is to achieve greater utility as a diag-
nostic, prognostic, or theranostic marker; newer agents are in
development that are designed for that goal. Cyclooxyge-
nase (COX), the inhibition of which was the basis for early
trials of NSAIDs, is the focus of tracer development aimed
at creating isoform-specific (COX-1 and COX-2) agents.
Although success in this endeavor will be valuable, radioli-
gands for other markers, such as targets within the signaling
cascades for pro- and anti-inflammatory cytokine production
and release, as well as for phagocytosis are greatly desired.
Astrocyte-specific and microglia-specific tracers would be
especially helpful [29].
Another promising biomarker for neuroinflammation in
AD is YKL-40 (also known as chitinase 3-like protein 1),
which is expressed in astrocytes and present in the CSF.
Studies have shown that YKL-40 levels increase in AD
and other neurodegenerative diseases even in their early
stages, correlate with other markers of neurodegeneration
(e.g., total tau and phosphorylated tau [p-tau]) and nega-
tively correlate with measures of cortical thickness in tempo-
ral regions of the brain [30,31]. Furthermore, in early AD
patients, CSF YKL-40 is related to a structural patterndistinct from that found to be linked to p-tau-associated neu-
rodegeneration presenting a nonlinear corelation with
cortical thickness. These results support the presence of
concomitant neuroinflammatory and neurodegenerative pro-
cesses at AD initial clinical stages and suggest that YKL-40
could be useful in tracking inflammatory processes related to
AD neurodegeneration [32]. CSF levels of various well-
known cytokines have also been explored as biomarkers of
neuroinflammation; however, data regarding their variability
and change in the course of AD are lacking, as are standard-
ized, validated protocols for sample collection, storage, and
quantification. These problems limit the feasibility of using
such measures at this time.
There have also been many efforts to identify plasma
markers of neuroinflammation. Plasma YKL-40 levels corre-
lated only weakly with CSF levels [33]; the situation was
the same for other markers such as plasma progranulin [34]
and tau [35]. Neuroinflammatory markers were also included
in early plasma proteomic studies using the Luminex xMAP
technology in cohorts of reasonable size; however, the findings
were inconsistent [36]. More recent plasma proteomic studies
in AD have identified a number of markers that appear to be
affected by the disease and are also key members of various
inflammatory pathways, such as the complement system,
toll-like receptor signaling, and intracellular signaling cas-
cades associated with the production and release of pro- and
anti-inflammatory cytokines and chemokines [37]. However,
the specific markers vary from one cohort to another, suggest-
ing substantial heterogeneity in study populations and assay
performance [38]. Nonetheless, these investigations have sug-
gested that further research may reveal plasma biomarkers, or
more likely a panel of markers, that could bemeasured consis-
tently and may be used for diagnosis, prognosis and in clinical
trials. Moreover, emerging proteomic technologies such as
aptamer-based technologies are providing better coverage of
some of these pathways.
Other novel approaches include studies of circulating
exosomes, which are membranous vesicles that are released
by neurons, astrocytes and microglia. In a recent study
comparing AD subjects and controls at two time points,
neuronal derived plasma exosomes from AD subjects con-
tained elevated levels of markers of amyloid pathology
and neurodegeneration (Ab42, total tau, and p-tau,) that
nearly perfectly discriminated AD from controls [39].
Intriguingly, in a longitudinal sample, the study also re-
vealed that the elevations were present long before the onset
of cognitive impairment, suggesting that exosomes might be
a marker of preclinical AD.
Another approach of increasing interest is the use of
computational tools, informatics, and large-scale integrated
systems biology approaches to identify genetic nodes and
networks involved in immune system function. Two exam-
ples of the utility of these approaches are (1) identification
of an immune-specific andmicroglia-specific network domi-
nated by genes implicated in phagocytosis and up-regulated
in AD [40] and (2) demonstration of the promise of these
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tion, molecular circuits, and dynamics of the immune system
and to predict interactions of drugs and immune cells in a
system-wide manner [41,42].3.2. Animal models
Animal models are also essential for novel target explo-
ration, biomarker discovery, and drug development. Much
of the research described earlier regarding the subtypes of
microglia and their relationship to neuroinflammation and
the main AD pathologic hallmarks could only be accom-
plished in animal studies. Preclinical animal models have
been and continue to be important tools for AD drug discov-
ery and for exploration of pathogenic mechanisms [43–45].
Live imaging of microglia in mouse brain has demonstrated
the active responses these cells have to neuronal activity
[46]. The role of several genes implicated as risk factors
for Alzheimer’s disease while still unclear suggests an
important role for resident microglia in the efficient clear-
ance of Ab peptide from brain parenchyma [47]. Yet, there
is a clear need for more predictive animal models that more
accurately reflect human pathogenesis. This represents a
particular problem in the study of neuroinflammation and
neuroimmunity for several reasons. First, there are substan-
tial differences between the immune systems of rodents and
humans. Second, most laboratory animals are raised in
pathogen-free conditions, so that they are never exposed
to pathogens that are commonly encountered by humans
which shape both innate and adaptive immune responses.
Finally, aging has not been well addressed using animal
models. Although the NIH houses an aged mouse reposi-
tory, it remains extremely costly to maintain animals to
advanced age mirroring the common late-life incidence of
AD in humans. Amajor advance in the past 2 years in regard
to generating more predictive models has been the emer-
gence of CRISPR/Cas9 genome editing [48], which has
the potential to revolutionize the generation of animal and
cell models.4. Translational research
New translational research approaches are also needed to
clarify how aging and chronic systemic disease affect BBB
permeability, immune cell profiles, and homeostasis in the
CNS. For example, the relationship among astrocytes, mi-
croglia, and neurons is complex and context-specific; and
other immune cells such as pericytes may also play impor-
tant roles in maintaining BBB integrity. In addition, periph-
eral inflammatory cells or mediators can contribute to
neuroinflammatory responses, especially in situations of
compromised BBB integrity. An improved understanding
of these and related processes could enable development
of mechanism-based immunomodulatory therapies to
restore immune cell homeostasis and delay/attenuate synap-
tic dysfunction in AD.Research on IL-12 and IL-23 represents an example of
how a translational program could advance both our under-
standing of neuroinflammation in AD and therapeutics tar-
geting it. It is known that CSF levels of IL-12 and IL-23
are increased in AD. Studies in AD mouse models indicate
that these immune mediators are released by activated mi-
croglia and that blocking their signaling reduces cerebral
amyloid burden [49]. Inhibitors of IL-12 and IL-23 have
already been tested in clinical trials for other diseases and
thus could be available for testing in AD [5]. Another
example of a productive translational approach currently un-
der investigation involves leveraging research on neuroin-
flammation in Parkinson’s disease (PD) to advance
understanding of this process in AD. Tansey et al. hypothe-
sized that neutralizing soluble TNF-a could reduce neuronal
damage and loss. Testing this strategy in a rat model of PD,
they showed that XPro1595, a dominant-negative TNF-a in-
hibitor selective for the soluble form of the cytokine reduced
the numbers of microglia and astrocytes and attenuated the
loss of dopamine neurons [50]. They also tested this strategy
in a transgenic AD mouse model, where they showed that
XPro1595 modulated immune cell populations in both the
CNS and periphery and improved electrophysiological mea-
sures and synaptic plasticity.
Although genome-wide association studies (GWASs)
have identified a number of genetic variants associated
with AD, such as TREM2, GWAS does not provide informa-
tion on the causal single-nucleotide polymorphism or the
gene that is affected. However, conjoint GWAS and protein
expression studies have provided insight about how various
genes and gene products affect the function of monocytes in
AD models and subjects. For example, such studies have
confirmed patterns of gene expression modulation unique
to monocytes and T cells with AD and PD loci compared
to patterns in other diseases such as MS. Specifically, gene
expression is modulated in monocytes but not T cells at
AD and PD loci, whereas the opposite is true in MS and
rheumatoid arthritis [51].
Targeted analysis of the TREM locus, combined with en-
dophenotyping in several large cohorts of elderly individ-
uals, has revealed additional details about the functional
consequences of different gene variants that confer either
increased risk or protection against plaques and cognitive
decline [52]. Similar studies focused on other loci have
also provided insight into the interaction of CD33,
TREM2, TREM1, and other proteins, which determine
whether monocytes will have a risk or protective phenotype.
Eventually, these studies could provide clarity about how
best to modulate monocytes therapeutically.5. Path toward novel treatments
5.1. Innate immunity—increase or decrease?
Despite substantial progress in the field, uncertainty re-
mains regarding the central question of whether
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munity. A number of research findings argue in favor of
increasing innate immunity by activating microglia:
 Some microglia activation responses, including those
induced by TLR activation, complement activation, or
cytokine overproduction, can lead to reduced amyloid
plaque deposition in amyloid depositing mice [53].
 Mice lacking the microglial receptor CX3CR1, which
have altered microglia activation because of the disrup-
tion of CX3CL1-CX3CR1 signaling between micro-
glia and neurons, show reduced Ab deposition [54].
 Mice lacking the microglial CCR2 chemokine receptor
show impaired microglial function, decreased clear-
ance of Ab, and accelerated progression of AD [55].
Support for decreasing innate immunity includes data
showing that
 Experimental manipulations that increase microglia
activation, such as LPS administration, IL-1b overex-
pression, and deletion of CX3CL1, leads to exacerba-
tion of tau pathology in tau-depositing AD mouse
models [53,56–58].
 Immune reactions regulate amino acid catabolism and
reduce the production of arginine in microglia, which
results in neuronal death [59].
 Chronic elimination ofmicroglia inADmodelmice res-
cues dendritic spine loss, prevents neuronal loss, and
improves cognitive performance in contextual memory
tests [60].
These examples illustrate that there is not a simple answer
to whether innate immunity should be increased or
decreased. The previous classification of inflammatory re-
sponses of microglia and/or macrophages into M1 (classical
inflammatory activation, secretion of proinflammatory cyto-
kines, and other tissue damaging molecules) and M2 (alter-
native activation associated with tissue repair and
inflammatory resolution) is now known to be too simplistic.
These cells can assume a broad spectrum and complexity of
inflammatory phenotypes that are influenced by a number of
factors, including the activating stimuli, the timing, the cell
types involved, genetic components, and the microenviron-
ment [2,4]. These will be key issues to address in any
therapeutic strategies targeting neuroinflammation.
The idea of beneficial versus detrimental microglia
responses is also evolving. It is becoming clear that inflamma-
tory responses in the CNS are often accompanied by
up-regulation of molecules that suppress or resolve neuroin-
flammation. There appears to be a complex interplay among
multiple cell types in theAD brain that can change the balance
between proinflammatory mediators and neuroinflammatory
modulators; this imbalance results in either neuroprotective
or neurotoxic consequences [61,62]. Adding to the degree
of complexity are recent reports that cytokines typically
thought of as pro-inflammatory (TNFa, IL-6) or anti-
inflammatory (IL-10, TGF-b) can have dichotomous rolesdepending on concentration, target cell, receptor subtype,
and disease stage. For example, studies have demonstrated
beneficial effects of blocking anti-inflammatory IL-10
[63,64] or TGF-b [65] signaling in AD mouse models. These
data suggest that therapeutic approaches aimed at rebalancing
innate immunity to a healthy state, typically approached
by selective suppression of pro-inflammatory responses,
should also explore the effectiveness of blocking key anti-
inflammatory cytokine action.
And what is the impact of age? Few mouse studies have
considered the effect of age on innate immune activity;
yet, in older humans, microglia rendered dystrophic and
dysfunctional by aging-related processes may contribute to
neurodegeneration, and there is evidence that microglia un-
dergo priming with normal aging, predisposing them to
exaggerated responses to pro-inflammatory stimuli. Indeed,
mouse models have generated a great deal of confusion and
contradictory data with regard to understanding neuroin-
flammation in AD and how to modulate it to improve clinical
outcome by transforming microglia from a neuroinflamma-
tory to neuroprotective phenotype.5.2. Targeting adaptive immunity
Under normal conditions, cells of the adaptive immune
system are not found in substantial numbers in the brain. How-
ever, significant infiltration of peripheral immune cells occurs
in neuroinflammatory conditions, and the responses of infil-
trating cells can have a substantial impact on the neuroinflam-
matory environment and AD pathology progression [66–68].
Therefore, the role of adaptive immune cell responses and
whether there are temporal and spatial therapeutic windows
for effective intervention are areas of increasing interest.
This interest is especially important given the prevalence of
therapeutic approaches using Ab immunization that engage
the adaptive immune system. Increased infiltration of
monocytes/macrophages, lymphocytes, and T cells into the
brain occurs with age and is seen in AD mouse models and
human AD brain. Whether the consequences are detrimental
or beneficial is complex. The role of adaptive immunity
appears to be influenced by a number of factors, including
the stage of disease progression, the repertoire of
inflammatory insults, and the ratio of specific immune cells
types. Using T cells as an example, infiltrating Th1 cells
were historically considered to be associated with increased
inflammation, impaired synaptic plasticity and cognitive
function, and amyloid accumulation, whereas Th2 cells and
Tregs were usually associated with reduced inflammation,
improved cognitive performance, and lower amyloid burden.
However, this is certainly an oversimplification, as there are
a number of reports that indicate both positive and negative
effects of all of these T cell subtypes in AD. For example,
infiltrating CD41 T cells have been reported to produce
interferon-gamma, promote microglia activation and increase
amyloid burden [66]. In contrast, it has been suggested that
infiltrating CD41 T cells and peripheral blood-derived
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local inflammatory responses, and that AD represents an
imbalance in this protective mechanism [68].
Even without cell infiltration, the presence of systemic
inflammation is communicated to the brain. Systemic
inflammation induced by a variety of stimuli has been re-
ported to lead to microglia priming, increased production
of proinflammatory molecules in the brain, and acceleration
of disease progression in AD animal models [69]. Recogni-
tion of the cross-talk between systemic and central inflam-
mation has important implications for AD therapeutic
strategies. However, translation of these conceptual ad-
vances to the clinic will require a fuller untangling of the mo-
lecular and bidirectional communication pathways between
the adaptive and innate immune systems. These studies must
consider the diverse nature of inflammatory responses at
different stages of disease progression and the distinct tem-
poral and spatial contributions of specific inflammatory re-
sponses so that optimal preventive or therapeutic strategies
can be developed to maintain or restore immune balance.5.3. Lessons from trials of anti-inflammatory drugs
The roundtable reviewed the findings of the trials of
NSAIDs and other anti-inflammatory agents conducted
almost two decades ago, in an effort to appreciate lessons
from these negative trials that might enhance the chance of
success for studies anticipated to be conducted with agents
specifically targeting innate immunity. Among the factors
that could account for the negative results of the early trials
are inappropriate disease stage and inappropriate targets.
Most of the early trials were conducted inMCI or AD demen-
tia, so it is possible that such agents could be efficacious only
as preventive strategies. One trial (ADAPT) enrolled an
earlier-stage sample and tested the effects of the nonselective
COX inhibitor naproxen and the selective COX-2 inhibitor
celecoxib on cognitive change in noncognitively impaired
elderly with a family history of AD-like dementia. Although
a 2011 follow-up study of the ADAPT trial suggested possible
protective effects of naproxen in cognitively intact subjects, a
later 2013 follow-up study showed no effect in delaying time
to AD diagnosis [2]. It is thus also possible that COX is not a
key mediator of neuroinflammation in AD. Notably, the early
trials did not have the benefit of two factors discussed above
that are likely to be critical for the success of future trials,
namely, the need for prior positive data in appropriate animal
models and the availability of relevant biomarkers.
Several recent or planned investigational efforts aim to
treat neurodegenerative disease by modulating immunity
and neuroinflammation. Table 1 lists clinical trials of selected
Alzheimer’s drug candidates with anti-inflammatory activity.
In PD, both innate and adaptive immunity have been
shown to affect disease progression. Using a mouse model
of PD, researchers have explored an approach that both at-
tenuates neuroinflammation and induces neuroprotection[70] by shifting the balance of anti-inflammatory regulatory
T cells (Treg) and neurodestructive effector T cells (Teff).
Another approach, being pursued by CereSpir, attempts
to simultaneously stimulate microglial phagocytic activity
and blunt the production and release of cytokines that dam-
age tissue by leveraging astrocyte-microglia communica-
tion. CereSpir’s compound, CSP-1103, is a small molecule
derived from a NSAID scaffold but with COX-1 inhibition
substantially reduced and COX-2 inhibition entirely
removed. It has shown beneficial effects on amyloid plaques
and several biomarkers of neuroinflammation in transgenic
mouse models as well as good safety and tolerability in
phase 1 and 2a studies [71]. An adaptive phase 2b/3 trial
of CSP-1103 in MCI due to AD is being planned.
Retinoid X receptor (RXR) agonists have also been under
investigation for the treatment of AD. Retinoids modulate
many cellular functions including immune responses [72].
RXR agonists heterodimerize with retinoic acid receptors
(RARs) to regulate gene expression [73]. Studies have sug-
gested that PPARg binds with RXR to induce APOE-HDL
synthesis and subsequent soluble Ab degradation [74]. Bex-
arotene is an RXR agonist that has been reported in several
studies to increase APOE expression and microglial phago-
cytosis, reduce soluble Ab levels, and improve cognition
[75]; however, other studies suggest no beneficial effects
of bexarotene in AD model mice [76].
Finally, drugs that affect microglial priming and systemic
inflammation, such as the TNF-a blocker etanercept, are be-
ing investigated for use in AD. In a randomized, placebo-
controlled, double-blind phase 2 study in mild to moderate
AD, etanercept was well tolerated and showed some trends
toward cognitive, functional, and behavioral benefits [77].
A number of practical implications of the early studies
and more recent trials should be considered in planning
future trials with agents that target innate immunity,
including the need to determine the optimal treatment dura-
tion and the appropriate approach to diverse patient charac-
teristics that could affect therapeutic efficacy. The latter
include body weight/glucose intolerance, the microbiome,
comorbid illnesses, especially systemic inflammatory disor-
ders, and the impact of anti-inflammatory medications used
for such illnesses. All these factors have either demonstrated
or theoretical potential to affect CNS innate immunity, thus
possibly affecting the results of agents to be tested for AD.5.4. Barriers and challenges to clinical development
Several impediments to clinical development of treat-
ments for neuroinflammation in AD must be overcome for
the potential benefit of this therapeutic strategy to be real-
ized. Besides those revealed by the failure of early clinical
trials discussed above, one substantial obstacle is funding.
Some older agents currently approved for other indications
might be repurposed for AD, an example being RXR ago-
nists. The bexarotene study, although failing to show bene-
fits, illustrates the ability to translate the results of animal
Table 1
Clinical trials of selected Alzheimer’s drug candidates with anti-inflammatory activity
Candidate ClinicalTrials.gov Identifier(s)
Clinical
phase Summary
Albumin and
Immunoglobulin
NCT01561053 III Naturally occurring antibodies with anti-inflammatory and immunomodulating
properties.
ALZT-OP1 NCT02547818, NCT02482324 III A combination drug therapy consisting of two previously approved drugs. Cromolyn
inhibits beta-amyloid peptide polymerization, and lowers cytokine production while
Ibuprofen inhibits the neuroinflammatory response.
Atomoxetine
(Strattera)
NCT01522404, NCT00191009 II Atomoxetine is a norepinephrine uptake inhibitor approved for ADHD. Eli Lilly
conducted a 6-month phase 2/3 trial to evaluate the effectiveness of atomoxetine in
92 subjects with mild to moderate AD. Atomoxetine was reported to be generally
safe; however, it did not benefit cognition in these patients.
Bexarotene
(Targretin)
NCT01782742, NCT02061878 II Bexarotene is approved for the treatment of some cancers. It is an RXR agonist that has
been reported in several studies to increase APOE expression and microglial
phagocytosis, reduce soluble Ab levels, and improve cognition [54].
Cerefolin NAC
(CFLN)
NCT01745198, NCT00597376 Not
active
Homocysteinemia is associated with increased risk for AD, coronary artery disease,
and stroke. Cerefolin or Cerefolin NAC (CFLN) has been shown to lower
homocysteine levels.
CSP-1103
(CHF 5074)
NCT01303744, NCT01258452,
NCT01203384, NCT00954252
II Selectively reduces pro-inflammatory activities of microglial cells while increasing
their ability to remove neurotoxic amyloid beta aggregates.
Curcumin NCT01811381, NCT00164749,
NCT00099710, NCT01383161
II Plant extract, dietary supplement; thought to have anti-inflammatory and antioxidant
properties, and to bind and clear amyloid.
Etanercept
(Enbrel)
NCT01068353, NCT01716637,
NCT00203359, NCT00203320
II TNF-a blocker. In phase II, etanercept was well tolerated and showed some trends
toward cognitive, functional, and behavioral benefits [56].
GC 021109 NCT02254369, NCT02386306 I GC 021109 reportedly binds the microglial P2Y6 receptor and to stimulate both
microglial phagocytosis and inhibit microglial release of pro-inflammatory
cytokines such as IL-12.
Genistein NCT01982578 II Genistein is an isoflavone that is present in soybeans and other plants. It acts as a PPARg
agonist with antioxidant and anti-inflammatory properties.
Lipoic
acid/Omega-3
NCT01780974, NCT01058941, II Lipoic acid is proposed to have anti-inflammatory and neuroprotective properties. A
trial is recruiting exploring the effects of lipoic acid in combination with Omega-3
for Alzheimer’s prevention.
Minocycline NCT01463384 II Minocycline is a tetracycline antibiotic, which crosses the blood-brain barrier. In some
animal models, minocycline reduces the Aß accumulation, the levels of pro-
inflammatory mediators and the activation of microglia. A small phase II trial with
13 participants with MCI and AD was completed in 2014 where subjects were
administered 50-mg minocycline twice daily for 6 months. No significant safety
issues were reported.
Nabilone
(Cesamet)
NCT02351882 III A D9-tetrahydrocannabinol (THC) analogue, potentially with neuroprotective and anti-
inflammatory properties. It is FDA approved as a pain killer and anti-nausea agent for
people receiving cancer treatment.
Pioglitazone NCT01931566, NCT02284906,
NCT00982202
III Pioglitazone is a PPARg agonists approved as a once-daily treatment of type 2 diabetes.
PPARg activation has been shown to modulate the microglial response to amyloid
deposition in such a way that it increases Ab phagocytosis and decreases cytokine
release.
Sargramostim
(Leukine)
NCT01409915, NCT02667496 II A recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that
functions as an immunostimulator and is approved for the treatment of cancer. In
Alzheimer’s, it may increase the phagocytosis of pathogenic protein deposits by
bone marrow–derived macrophages or brain-resident microglia and may also
stimulate other neuroprotective innate immunity processes.
Simvastatin
(Zocor)
NCT01439555, NCT00842920,
NCT00053599, NCT01142336,
NCT00486044, NCT00939822,
NCT00303277
II Simvastatin is approved to lower blood cholesterol levels by inhibiting HMG-CoA
reductase (a statin drug). Two trials are ongoing in Alzheimer’s with simvastatin
alone or in combination with L-arginine and tetrahydrobiopterin.
VX-745 NCT02423200, NCT02423122 II VX-745 is a blood-brain barrier penetrant, selective p38 MAPKa inhibitor.
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relatively small sum of money. In addition, two other RXR
agonists are currently in development.
It is also generally appreciated that funding limitations
constrain drug discovery and development efforts for ther-
apeutic strategies outside the mainstream amyloid and tau
hypotheses. This state of affairs is particularly problem-atic for academic groups and small biotech firms striving
to advance treatments for neuroinflammation. Despite
rapid and dramatic advances in the technology and meth-
odology for target identification and evaluation, this work
and the early stages of drug discovery for promising hits
and leads arising from it remain long, complicated, and
uncertain.
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inflammatory treatments for AD is the lack of high-quality
observational data for biomarkers of interest in well character-
ized samples that could support the use of such measures for
either enrichment purposes or as indicators of target engage-
ment measures. Some roundtable participants suggested that
to gain a clearer picture of neuroinflammation across the con-
tinuum of the disease, relevant biomarkers should be evalu-
ated longitudinally in observational studies such as ADNI.
In this regard, there is increasing interest in developing and
validating neuroimaging agents that reflect specific aspects
of neuroinflammation, for use in diagnosis, monitoring treat-
ment effects, and guiding development of new therapies
[78]. An exploration of the mechanisms underlying cognitive
resilience was also suggested as essential in understanding the
role of neuroinflammation and immune mechanisms.6. Conclusions and key areas for future research
Although a number of epidemiologic studies have linked
anti-inflammatory treatment to a lower AD risk, prospective
clinical trials with NSAIDs and some other types of
anti-inflammatory agents have so far failed to demonstrate
efficacy. The reasons for these failures have yet to be fully
elucidated, but the rapid pace of basic science research on
mechanisms underlying the derangement of the innate im-
mune system in AD augurs the need for key information to
provide a clearer understanding in coming years.
A very important area for future research is to define the
molecular characteristics and significance of neuroinflam-
mation at different stages of AD. Some evidence supports
the notion that the inflammatory response of both astrocytes
and microglia may peak during the beginning of the symp-
tomatology, that is, during MCI. Clarifying this will be
crucial to development programs for new agents.
It is increasingly clear that innate immunity is pathogeneti-
cally important in AD and possibly even central to disease
progression; however, proof of a role for adaptive immunity
remains limited. Recent evidence suggests that in response
to Ab vaccination, products of adaptive immunity (B cells
and immunoglobulins directed against Ab) may turn micro-
glia into Ab fighters but this requires more study.
It is also important to remember that AD is associated
with both a loss of physiological function and a potential
gain of toxic function. Effective treatment will require
restoring cells to health, not simply dampening down delete-
rious processes. In this regard, it is notable that strategies to
restore the deficient phagocytic capacity of microglia have
beenmuch less explored to date compared to research target-
ing cytokine reduction.
In general, roundtable participants agreed that the roles of
neuroinflammation and the innate immune system in aging
and AD are far more complicated than initially thought.
There are a number of important aspects of the immune sys-
tem that have yet to be adequately investigated, as well as ge-
netic and epigenetic mechanisms that are likely to playimportant roles. The influence of neuropsychiatric distur-
bances such as depression, agitation, and psychosis that
frequently complicate AD dementia may also be important
to evaluate, as research is demonstrating inflammatory
mechanisms in primary psychiatric disorders such as major
depression and schizophrenia [79]. Improved fluid and im-
aging biomarkers, banking of biospecimens, and endophe-
notyping of the “neuroinflammation state” of the brain
before and during disease will be required to design trials
that will demonstrate efficacy in appropriate individuals
and thus optimally advance effective anti-inflammatory
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1. Systematic review: We reviewed the literature of
recent work exploring the important roles of inflam-
mation and immunemechanisms on Alzheimer’s dis-
ease (AD).
2. Interpretation: The present article posits that innate
immune cells, particularly microglia and astrocytes,
mediate neuroinflammation in AD, which is a signif-
icant contributor to disease pathogenesis. Adaptive
immunity may also contribute to neuroinflammation
in AD.
3. Future directions: A better understanding of the
complexity of neuroinflammation and the innate im-
mune system in aging and AD is needed to discover
new targets and biomarkers that will lead to novel
therapeutic approaches.
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